CTOs on the Move

Vivodyne

www.vivodyne.com

 
Vivodyne accelerates the successful discovery, design, and development of human therapeutics through the convergence of novel biology, robotics, and AI. Our platform enables customers to massively de-risk drug candidates by testing them against functional, lab-grown, human organs and multi-organ systems. We conduct preclinical discovery and clinical development campaigns to generate new therapeutic strategies from these proprietary, physiologically-realistic organs at unprecedented scale, speed, and quality through automation and machine learning. We`re financially backed by some of the most selective and successful venture funds, and several “Top 10” global pharmaceutical innovators have already partnered with us to expand, strengthen, and accelerate their ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.vivodyne.com
  • 601 Walnut Street Suite 775
    Philadelphia, PA USA 19106
  • Phone: n/a

Executives

Name Title Contact Details
Elliot Menschik
Chief Technology Officer and Member of Board of Directors Profile

Similar Companies

Tectonic Therapeutic

Tectonic, co-founded by Andrew Kruse and Tim Springer of Harvard Medical School, is transforming the discovery of antibodies and other biologic drugs targeting G-protein Coupled Receptors (GPCRs). With our proprietary GEODe™ platform, we are targeting the most difficult, previously undruggable receptors in the class, aiming to unlock their therapeutic utility to develop new treatments for a broad range of patients with important unmet needs.

Biotech Medical

Biotech Medical is a Canton, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Astex Pharmaceuticals

Astex Pharmaceuticals is a Dublin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MitoSciences Inc

MitoSciences Inc is a Eugene, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Century Therapeutics

Our genetically-engineered, universal iPSCs-derived immune effector cell products (NK, T, Dendritic cells, and macrophage) are designed to specifically target hematologic and solid tumor cancers. Our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care.